Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD).
Date: February 23-24, 2004.
Time: 9 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: Gaithersburg Marriott Washington Center, 9751 Washington Boulevard, Gaithersburg, MD 20878.
Contact Person: Eleazar Cohen, Phd, Scientific Review Administrator, Scientific Review Program, National Institute of Allergy and Infectious Diseases, DEA/NIH/DHHS, 6700 B Rockledge Drive, MSC 7616, Room 3112, Bethesda, MD 20892-7616, 301-435-3564, email@example.com.Start Signature
(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856; Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)
Dated: January 28, 2004.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 04-2387 Filed 2-4-04; 8:45 am]
BILLING CODE 4140-01-M